On July 1, 2019, the Washington State Health Care Authority (HCA) announced it signed a contract with AbbVie U.S., LLC to provide medication to treat hepatitis C virus (HCV) under a volume-based alternative payment model. The model implements an expenditure cap to ensure cost control while simultaneously increasing the potential to treat people diagnosed with HCV. The state’s goal is to eliminate HCV in Washington by 2030. The state selected AbbVie following a competitive procurement released on January 22, 2019. The initial contract period is slated to run from July 1, 2019 to June 30, 2023, with . . .